IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is highly heterogeneous. Here, the authors perform exome sequencing and bulk RNA sequencing on 73 tumor regions from 14 ICC patients to portray the multi‐faceted intratumor heterogeneity (ITH) landscape of ICC. The authors show that ITH is highly concordant across genomic, transcriptomic, and immune levels. Comparison of these data to 8 published datasets reveals significantly higher degrees of ITH in ICC than hepatocellular carcinoma. Remarkably, the authors find that high‐ITH tumors highly overlap with the IDH (isocitrate dehydrogenase)‐mutant subgroup ( IDH ‐SG), comprising of IDH ‐mutated tumors and IDH ‐like tumors, that is, those IDH ‐wildtype tumors that exhibit similar molecular profiles to the IDH ‐mutated ones. Furthermore, IDH ‐SG exhibits less T cell infiltration and lower T cell cytotoxicity, indicating a colder tumor microenvironment (TME). The higher ITH and colder TME of IDH ‐SG are successfully validated by single‐cell RNA sequencing on 17 503 cells from 4 patients. Collectively, the study shows that IDH mutant subgroup status, rather than IDH mutation alone, is associated with ITH and the TME of ICC tumors. The results highlight that IDH ‐like patients may also benefit from IDH targeted therapies and provide important implications for the diagnosis and treatment of ICC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In conclusion, much remains to be discovered, but cholangiocarcinoma is a highly desmoplastic and cold tumor with low immune cell infiltration and heterogeneous intratumor areas [219, 220].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [220]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Efremova, M., Vento-Tormo, M., Teichmann, S. A., & Vento-Tormo, R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0292-x · Cited by 3,449
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Research works printed but not linked: 1
- 10.1016/j.cell.2017.05.046 · DOI · Paper page
Cited by
Liver tumour immune microenvironment subtypes and neutrophil heterogeneity
Xue, R., Zhang, Q., Cao, Q., Kong, R., Xiang, X., Liu, H., Feng, M., Wang, F., Cheng, J., Li, Z., et al. (2022) · Nature · doi:10.1038/s41586-022-05400-x · Cited by 935
Self-citationImmunology and immunotherapy of cholangiocarcinoma
Greten, T. F., Schwabe, R., Bardeesy, N., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00741-4 · Cited by 193
Yang, H., Cheng, J., Zhuang, H., Xu, H., Wang, Y., Zhang, T., Yang, Y., Qian, H.-G., Lu, Y., Han, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.004 · Cited by 187
Self-citation(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
“In conclusion, much remains to be discovered, but cholangiocarcinoma is a highly desmoplastic and cold tumor with low immune cell in fi ltration and heterogeneous intratumor areas [219, 220].”
Guo, L., Yi, X., Chen, L., Zhang, T., Guo, H., Chen, Z., Cheng, J., Cao, Q., Liu, H., Hou, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.08.052 · Cited by 86
Self-citationLin, Y., Peng, L., Dong, L., Liu, D., Ma, J., Lin, J., Chen, X., Lin, P., Song, G., Zhang, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1640 · Cited by 90
Liu, H., Gao, J.-W., Feng, M., Cheng, J., Tang, Y., Cao, Q., Zhao, Z., Meng, Z., Zhang, J., Zhang, G., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.012 · Cited by 87
Self-citationBiology of IDH mutant cholangiocarcinoma
Wu, M., Shi, L., Merritt, J., Zhu, A. X., & Bardeesy, N. M. (2022) · Hepatology · doi:10.1002/hep.32424 · Cited by 74
Cheng, M., Liang, G., Zongyi, Y., Lin, X., Sun, Q., & Liu, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04498-w · Cited by 63
Cancer immunometabolism: advent, challenges, and perspective
Dang, Q., Li, B., Jin, B., Zeng, Y., Lou, X., Wang, T., Wang, Y., Pan, X., Hu, Q., Li, Z., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01981-5 · Cited by 63
“IDH mutations are highly correlated with the degree of intra-tumor heterogeneity, and IDH mutations produce a paracrine metabolite, (R)-2-hydroxyglutarate, which can be involved in shaping the tumor immune microenviron - ment [146, 147].”
BackgroundSelf-citationZuyin, L., Zhao, L., Qian, C., Changkun, Z., Ma, D., Jialing, H., Zhuomiaoyu, C., Li, Y.-Z., Jiaxi, Z., Jie, G., et al. (2024) · Advanced Science · doi:10.1002/advs.202412740 · Cited by 63
Self-citationWang, T., Xu, C., Zhang, Z., Wu, H. J., Li, X., Zhang, Y., Deng, N., Dang, N., Tang, G., Yang, X., et al. (2022) · Hepatology · doi:10.1002/hep.32483 · Cited by 57
“Consistent with our previous observation, ICC tissues were CK19- positive, with typical glandular structure but no lipid droplets, although AKT is a potent de novo lipogenesis driver in HCC.[11,12] Therefore, we chose mouse ICC tissues collected on days 10, 17, and 31 as representatives of the early, middle, and late…”
BackgroundSelf-citationWu, L., Li, X., & Yan, J. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101995 · Cited by 56
Targeting Mitochondrial Metabolic Reprogramming as a Potential Approach for Cancer Therapy
Zhang, L., Wei, Y., Yuan, S., & Sun, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054954 · Cited by 46
“IDH Mutations are associated with highly heterogeneous tumor microenvironments, suggesting that targeting IDH mutations may effectively treat cancer [37].”
BackgroundMoore, J. A., Chen, K., Madison, R. W., Newberg, J. Y., Fleischmann, Z., Wang, S., Sharaf, R., Murugesan, K., Fendler, B. J., Hughes, J. D., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00093 · Cited by 39
IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
Brandi, G., & Rizzo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810869 · Cited by 34
Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
Carosi, F., Broseghini, E., Fabbri, L., Corradi, G., Gili, R., Forte, V., Roncarati, R., Filippini, D. M., & Ferracin, M. (2024) · Cancers · doi:10.3390/cancers16152752 · Cited by 31
“In addition to this, Ivosinedib resistance has been also linked to the increased expression of immunomodulating receptors on neoplastic cells, like PD-L1 and CTLA-4 [115,116].”
BackgroundGupta, A., Kurzrock, R., & Adashek, J. J. (2023) · Cancers · doi:10.3390/cancers15051578 · Cited by 29
“IDH1 gene mutations commonly occur in CCA [108].”
BackgroundMolecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy
Ivanov, S., Nano, O., Hana, C. K., Bonano-Rios, A. M., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137337 · Cited by 28
“In mice models, IDH mutation with the resultant elevation in 2-HG promoted cholangiocarcinoma tumor maintenance through an immune evasion program centered on dual 2-HG-mediated mechanisms: suppression of CD8+ T-cell activity and tumor cell-autonomous inactivation of TET2 DNA demethylase [30].”
BackgroundWeng, J., Ju, F., Lyu, Z., Fan, N., Smit, D. J., Xu, W., Wu, X., Becker, P., Xu, Y., Schweiger, M. R., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03567-5 · Cited by 28
“In addition, Xiang et al. reported that ICC has significantly higher degrees of intra-tumoral heterogeneity than HCC [137].”
Effects of metabolic cancer therapy on tumor microenvironment
Hyroššová, P., Milošević, M., Škoda, J., Vachtenheim, J., Jr., Rohlena, J., & Rohlenová, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1046630 · Cited by 25
Hu, X., Zhao, M., Bai, M., Xue, Z., Wang, F., Zhu, Z., Yu, J., & Yue, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216676 · Cited by 22
Tang, N., Li, J., Gu, A., Li, M., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00330-2 · Cited by 21
“…genes IDH1/2 or FGFR2 fusions), amplification biases can distort gene expression quantification, and single-cell technology itself cannot capture the in situ spatial information of cells, making it challenging to analyze the spatial regulatory mechanisms within the microenviron - ment [67, 81].”
Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets
Wagner, M. J., Pimenta, E. M., Sweeney, N. W., Loggers, E. T., Roberts, J. L., Brinkmann, E. J., Chen, E. Y., Ricciotti, R. W., Haddox, C. L., Berg, R., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00592 · Cited by 20
Zhou, X., Zhang, B., Hu, J., Shen, J., Chen, Z., Zhang, J., Wu, B., Zhou, E., Peng, S., Wong, T., et al. (2024) · The Innovation Medicine · doi:10.59717/j.xinn-med.2024.100052 · Cited by 20
Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes
Chen, Z., Gao, J., Li, Z., Ma, D., Wang, Y., Cheng, Q., Zhu, J., & Zhao, L. (2024) · Liver International · doi:10.1111/liv.16015 · Cited by 17
Self-citationNishida, N., Aoki, T., Morita, M., Chishina, H., Takita, M., Ida, H., Hagiwara, S., Minami, Y., Ueshima, K., & Kudo, M. (2023) · Cancers · doi:10.3390/cancers15082379 · Cited by 17
“Studies reported that IDH1/2 mutations could shape a “cold immune microenvironment” [34,35].”
BackgroundPotential therapies targeting nuclear metabolic regulation in cancer
Chen, Y., Xu, J., Liu, X., Guo, L., Yi, P., & Cheng, C. (2023) · MedComm · doi:10.1002/mco2.421 · Cited by 16
“40,42,43”
Heterogeneity of small duct‐ and large duct‐type intrahepatic cholangiocarcinoma
Kinzler, M. N., Schulze, F., Jeroch, J., Schmitt, C. R., Ebner, S., Gretser, S., Bein, J., Finkelmeier, F., Trojan, J., Zeuzem, S., et al. (2024) · Histopathology · doi:10.1111/his.15162 · Cited by 14
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions
Zhang, G., Li, J., Li, G., Zhang, J., Yang, Z. P., Yang, L., Jiang, S., & Wang, J. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01460-7 · Cited by 14
“As a result, both the quantity and functionality of T cells within cold tumors are reduced, leading to a suboptimal response to immune checkpoint inhibitors (ICIs) [71].”
BackgroundPorreca, V., Barbagallo, C., Corbella, E., Peres, M., Stella, M., Mignogna, G., Maras, B., Ragusa, M., & Mancone, C. (2024) · Cancers · doi:10.3390/cancers16162889 · Cited by 15
“Xiang and coworkers [115] combined a genomic approach with a transcriptomic one.”
BackgroundChen, W., Xu, D., Liu, Q., Wu, Y., Wang, Y., & Yang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114697 · Cited by 12
Liu, C. X., & Wong, C. C.-L. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0889 · Cited by 15
“In line with this result, IDH1 mutant CCA patient samples have been reported to harbor a colder TME with reduced immune cell infiltration [124-126].”
Current development and future perspective of IDH1 inhibitors in cholangiocarcinoma
Adeva, J. (2021) · Liver Cancer International · doi:10.1002/lci2.43 · Cited by 13
Liu, X., Luo, Z., Ren, X., Chen, Z., Bao, X., Zheng, J., & Zuo, Z. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.821232 · Cited by 13
“Oncogenic Events Associated With the Crosstalk Between Malignant Cells and Tumor-Promoting Immune Cells We next investigated the oncogenic events associated with the crosstalk (Xiang et al., 2021).”
BackgroundXu, S., Cao, L., Chen, R., Ye, C., Li, Q., Jiang, Q., Yan, F., Wan, M., Zhang, X., & Ruan, J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae132 · Cited by 10
“…thereby inhibiting histone and DNA demethylases, which in turn affects epigenetics, posttranslational modification of proteins, etc. 9 These cellular metabolic activity changes associated with IDH1 and IDH2 mutations also promote tumor development and enhance tumor cell metabolism.”
BackgroundResultIDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
Bray, A., & Sahai, V. (2025) · Current Oncology · doi:10.3390/curroncol32010044 · Cited by 10
Kinzler, M. N., Jeroch, J., Klasen, C., Himmelsbach, V., Koch, C., Finkelmeier, F., Trojan, J., Zeuzem, S., Pession, U., Reis, H., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04603-7 · Cited by 10
“observed a correlation between intratumoral heterogeneity and the IDH1 mutant subgroup (Xiang et al. 2021).”
BackgroundShen, X., Dong, P., Kong, J., Sun, N., Wang, F., Sang, L., Xu, Y., Zhang, M., Chen, X., Guo, R., et al. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3869 · Cited by 10
Self-citationAdvances in improving the efficacy of anti-PD-1/PD-L1 therapy in intrahepatic cholangiocarcinoma
Huang, S., Hua, C., Ding, B., Chen, J., Zheng, S., & Ding, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104784 · Cited by 9
Pu, X., Li, L., Xu, F., Wang, Z., Fu, Y. S., Wu, H., Ren, J., Chen, J., & Sun, B. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05894-0 · Cited by 8
“For instance, IDH mutant subgroupe exhibits less T cell infiltration and lower T cell cytotoxicity, indicating a colder tumor microenvironment (TME) (Xiang et al. 2021).”
BackgroundInfluentialMolecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy
Kabbara, K. W., Cannon, T. L., Winer, A., & Wadlow, R. C. (2022) · ONCOLOGY · doi:10.46883/2022.25920971 · Cited by 9
Li, W., He, H., Wang, H., & Wen, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217394 · Cited by 8
Dissecting the tumor ecosystem of liver cancers in the single-cell era
Wang, Y., Wang, P., Zhang, Z., Zhou, J., Fan, J., & Sun, Y. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000248 · Cited by 7
“Regarding T cell subtypes, CD8+ T cells in IDH-mutant tumors were naive, whereas CD8+ T cells in IDH-wild-type tumors were cytotoxic and exhausted.[81] Tumor stroma, including extracellular matrix, cancer vasculature, and various cells (eg, CAFs, tumor-associated endothelial cells, mesenchymal stromal cells, and peric…”
BackgroundWang, Y., Bai, H., Wang, A., Zhao, J., Guo, H., Tang, Y., Wang, Y., & Xie, Q. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70102 · Cited by 6
“This compound inhibited the activity of proteases with an IC 50 of 0.01 μM (Xiang et al. 2021).”
InfluentialLu, Y., Du, L., Sun, M., Zhang, K., Pang, M., Jiang, S., Dong, J., Liu, X. D., Jin, B., Xu, F., et al. (2026) · Advanced Science · doi:10.1002/advs.202522025 · Cited by 7
“However, pronounced interpatient heterogeneity in ICC leads to highly variable therapeutic responses [ 10 ], underscoring the urgent need for accurate, rapid, and cost-effective platforms to guide individualized treatment decisions.”
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy
Brown, Z. J., Ruff, S. M., & Pawlik, T. M. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2176846 · Cited by 6
“T cell infiltration and lower T cell cytotoxicity [18,19].”
Huang, H., & Chen, F. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00410 · Cited by 5
“22 In patients with IDH1 mutations, those treated with the IDH1 inhibitor ivosidenib show improved overall survival compared to the placebo group, thereby reinforcing the potential of targeted therapy in iCCA.”
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell Lymphomas
Johnson, P. C., & Abramson, J. S. (2022) · ONCOLOGY · doi:10.46883/2022.25920970 · Cited by 9
Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms
Choucair, K., Chamseddine, S., Azmi, A. S., & Philip, P. A. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1769447 · Cited by 3
Liang, Y., Zhang, R., Li, Y., Hao, W., Qiao, L., Bu, Q., Xu, Z., Liu, Z., Song, Z., Huang, T., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102750 · Cited by 3
“Recent advances in multi-omics technologies, particularly single-cell and spatial transcriptomics [11, 12], have enabled the comprehensive dissection of cellular composition, cell states, and intercellular interactions within tumors at single-cell and spatial resolution.”
Self-citationMutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon
Pan, S.-Y., Ye, Y.-H., Zhou, Z., Fan, J., Zhou, J., & Zhou, S. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2023.44 · Cited by 3
Genetic Uncertainties Fueling Cholangiocarcinoma Progression
Kadiri, S. K., & Tiwari, P. K. (2026) · Current Genomics · doi:10.2174/0113892029392506251115053421 · Cited by 2
“Liquid biopsies that examine circulating tumor DNA (ctDNA) and exosomes present promising non-invasive methods for early detection [79].”
Research on Targeted Therapy for Malignant Tumors of the Biliary Tract
Yang, Y., Zhong, H., Zhang, J., & Wang, P. (2026) · OncoTargets and Therapy · doi:10.2147/ott.s593457 · Cited by 2
Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity
Yang, J., Zhou, C. C., Kumar, S. V., Shay, C., & Teng, Y. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00795-z · Cited by 2
“Importantly, intratumoral variability in IDH mutation status or regional differences in D-2-HG production can generate metabolically and epigenetically distinct tumor subpopulations [59].”
Exploring Molecular Mechanisms in the Second-Line Treatment of Biliary Tract Malignant Tumors
Liu, Q., Zhang, P., & Li, Q. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.4 · Cited by 3
Chanda, M., Mekasuwandumrong, C., Wilasrusmee, K. T., Panich, U., & Jirawatnotai, S. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2025.15 · Cited by 6
Targeted mutation-based therapy for intrahepatic cholangiocarcinoma
Yang, F., Qiu, Y., & Yi, B. (2023) · Hepatoma Research · doi:10.20517/2394-5079.2023.68 · Cited by 1
Evaluation of an IDH1/2 Mutation FastTrack Assay for Patients with Cholangiocarcinoma
Winter, M., Ebner, S., Scheuber, N., Schulze, F., Kinzler, M. N., Walter, D. H., & Wild, P. J. (2025) · Cancers · doi:10.3390/cancers17050820 · Cited by 1
Lin, Y., Peng, L., Zhao, H., Lin, P., Chen, L., Gong, Z., Lin, J., Liu, D., Yang, X., Song, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102708 · Cited by 2
Recent progress of PROTACs in cancer immunotherapy
Liu, P., Chen, Q., & Li, J. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110042 · Cited by 1
Advances in Immunooncology and Precision Medicine in Cholangiocarcinoma
Brown, T. J., & Karasic, T. B. (2024) · Digestive Disease Interventions · doi:10.1055/s-0044-1787013
Li, Y., Chen, H., Zhang, B., Liu, J., Ma, J., Ma, W., & Lu, S. (2024) · ACS Omega · doi:10.1021/acsomega.4c01215
Chen, Y.-S., Li, J., Li, Y., Yang, W., Xu, J., Wei, Y., Huang, S.-M., Wang, Q.-W., & Jiang, X. (2024) · Research Square · doi:10.21203/rs.3.rs-5307501/v1
Cho, S. B. (2025) · Biomedicines · doi:10.3390/biomedicines13092263
“The IDH mutation subgroup of patients shows better prognosis and treatment response than patients with the wild-type IDH [7].”
Accurate detection of tumor clonality and ongoing expansion mode from genomic dataPreprint
Chen, Y., Jaksik, R., Terranova, P., Baghdadi, S. E., Koval, A., Kurpas, M. K., Tavaré, S., Kimmel, M., & Dinh, K. N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.15.732415
“Although the association between IDH mutation and elevated ITH has not been reported in LGG to our knowledge, mutant IDH has been linked to increased clonality in intrahepatic cholangiocarcinoma [Xiang et al., 2021] and acute myeloid leukemia [Sirenko et al., 2025].”
Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma
Qi, H., Pan, J., & Wu, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146228
“This mutation leads to accumulation of the metabolite 2-hydroxyglutarate, which suppresses T-cell function [115].”
Zhang, K., Du, L., Sun, M., Lu, Y., Pang, M., Jiang, S., Liu, X., Dong, J., Jin, B., Xu, F., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02751-1
“[9, 10] Molecular diversification across HCC, [11, 12] iCCA [13, 14], and combined hepatocellular cholangiocarcinoma (CHC) [15] further complicates treatment selection and contributes to variable therapeutic sensitivity and resistance.”
Intratumoral IDH1 mutation status in intrahepatic cholangiocarcinoma is homogeneous
Weidmann, S., Ebner, S., Srivastava, A., Wiegering, A., Zeuzem, S., Wild, P. J., Kinzler, M. N., Winter, M., & Walter, D. H. (2026) · Histopathology · doi:10.1111/his.70266
Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation
Xu, W., Shuhan, L. I. U., Sun, L., Bi, Y., Lin, Z., Wang, T., Ren, X., & An, R. (2026) · Oncogene · doi:10.1038/s41388-026-03961-z
Kim, R. D., Naleid, N., Bubie, A., Zhang, N. J., & Clemens, K. M. (2026) · Cancer · doi:10.1002/cncr.70646
“19,20 Despite the addition of immunotherapy as a new standard in BTCs, the benefit for patients with IDH1 - mutant cholangiocarcinoma remains unclear.”
Self-citation
Metadata
- Authors
- Xiang, X., Liu, Z., Zhang, C., Li, Z., Gao, J., Zhang, C., Cao, Q., Cheng, J., Liu, H., Chen, D., Cheng, Q., Zhang, N., Xue, R., Bai, F., & Zhu, J.
- Affiliations
- Department of Hepatobiliary Surgery, Peking University People's Hospital Beijing Key Surgical Basic Research Laboratory of Liver Cirrhosis and Liver Cancer Beijing 100044 China
- Peking University (CN)
- Peking University People's Hospital (CN)
- Peking University First Hospital (CN)
- Corresponding author
- Xue, Ruidong
- Bai, Fan
- Zhu, Jiye
- ORCID
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2021-07-11
- Volume
- 8
- Issue
- 17
- Pages
- e2101230-e2101230
- ISSN
- 2198-3844 (ISSN-L)
- PMC
- PMC8425914
- OpenAlex
- W3182403227
- Cited by
- 71
- References
- 57
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 21 · 2023: 12 · 2022: 10 · 2021: 3
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Advanced Science (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- National Science and Technology Major Project (2018ZX10302205, 2019YFC1315702, 2018ZX10723204)
- National Natural Science Foundation of China (81802813, 81988101, 81972656, 81570590, 81872508)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- intrahepatic cholangiocarcinoma, intratumoral heterogeneity, IDH mutation, tumor microenvironment, T cell infiltration, T cell cytotoxicity, tumor immune microenvironment, single-cell RNA sequencing
- MeSH terms
- Bile Duct Neoplasms, Humans, Isocitrate Dehydrogenase, Mutation, Cholangiocarcinoma, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.